A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus… (NCT03866317) | Clinical Trial Compass
WithdrawnPhase 2
A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus
Stopped: Difficulty recruiting participants
United States0Started 2019-09-01
Plain-language summary
Discoid lupus erythematosus is a chronic inflammatory skin condition and may lead to itch, skin pain, open sores, scarring, disfigurement and hair loss. Studies have shown that IL-17A may play a major role in inflammation and in the pathogenesis of discoid lupus. Treatment of discoid lupus sometimes is a challenge and unresponsive to current therapies. Secukinumab, an anti-IL-17A monoclonal antibody has been safe and effective in the treatment of psoriasis. The investigators propose to study the efficacy and safety of secukinumab in discoid lupus.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female subject 18 years of age or older
✓. Subjects with moderate to severe DLE with at least one active discoid target lesion (0.5-1.0 cm2), with CLASI ≥ 5.
✓. Willingness of subject to follow all study procedures
✓. Willingness to avoid excessive exposure of diseased areas to natural or artificial sunlight
Exclusion criteria
✕. Pregnancy or breast feeding
✕. Any condition or therapy that in the investigator's opinion may pose a risk to the subject or that could interfere with any evaluation in the study
✕. Systemic Lupus Erythematosus (SLE) as defined by ACR criteria
✕. Known hypersensitivity to any of the constituents or excipients of the investigational product
✕. Use of any prescription or non-prescription medication that could interfere with efficacy evaluations in the study
What they're measuring
1
To determine the efficacy of Secukinumab in Discoid Lupus Erythematosus by clinical responder rate at week 16.